Method and System for Treating Cancer and Other Age-Related Diseases by Extending the Healthspan of a Human

• US 20190307813A1
• Filed: 05/30/2019
• Published: 10/10/2019
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik, Katherine Rose Kovarik
• Inventors: Kovarik, Katherine Rose, Kovarik, Joseph E.
• Granted Patent: US 10,716,815 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2035/11 Medicinal preparations comprising living procariotic cells
• CPC Class Codes: A61K 2039/523 expressing foreign proteins
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 31/438 The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 38/1758 p53
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 39/07 Bacillus
• CPC Class Codes: A61K 39/35 Allergens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0034 : Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0043 : Nose
• CPC Class Codes: A61K 9/0053 : Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: C12Y 301/03048 : Protein-tyrosine-phosphatase (3.1.3.48)
• CPC Class Codes: C12Y 301/03067 : Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)

Abstract

Various embodiments of the present invention are directed to the field of Oncology, and in particular, embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. Certain embodiments are directed to the field of human longevity and aging in a manner such that cancer is not contracted due to ameliorating, treating, or reducing aging by increasing the healthspan and lifespan of humans. In certain embodiments, administration of beneficial bacteria to an individual'"'"'s microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, rapamycin, p53 protein, statins, etc., is employed to treat and prevent cancer and other age-related diseases.

Claims

1. A method of treating bladder cancer in a subject in need of such treatment, said method comprising administering to a microbiome of a subject with bladder cancer an effective amount of a bacterial composition comprising Bacillus calmette-guerin, said bacterial composition adapted to produce tomatidine and rapamycin.

2. The method of claim 1, wherein the bacterial composition comprises bacteria modified via a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system using a CRISPR-Cas system to express one of said tomatidine and rapamycin.

3. The method of claim 1, wherein the bladder cancer is a metastatic cancer.

4. The method of claim 1, wherein the microbiome is the gut microbiome.

5. The method of claim 1, wherein the microbiome is the oral microbiome.

6. The method of claim 1, wherein the microbiome is the skin microbiome.

7. A method of claim 1, wherein said bacterial composition further includes a microbe selected from the group consisting of Streptococcus, Actinomyces, Veillonella, Fusobacterium, Porphromonas, Prevotella, Treponema, Nisseria, Haemophilis, Eubacteria, Lactobacterium, Capnocytophaga, Eikenella, Leptotrichia, Peptostreptococcus, Staphylococcus, and Propionibacterium.

8. The method as set forth in claim 7, further comprising administering a bacterial composition to the subject that produces at least 0.1 mg of rayamycin.

9. The method of claim 1, wherein the bacterial composition has been modified via a CRISPR-Cas system to express rapamycin.

10. The method of claim 1, wherein the bacterial composition has been modified via a CRISPR-Cas system to express tomatidine.

11. The method of claim 1, wherein the bacterial composition further comprises one of a Chlamydia, Shigella flexneri, Mycoplasma bacteria, and H. pylori.

12. The method of claim 1, wherein the bacterial composition comprises H. pylori bacteria.

13. A method of treating bladder cancer in a subject in need of such treatment, said method comprising administering to a microbiome of a subject with bladder cancer an effective amount of a bacterial composition comprising a bacteria that has been modified to express a therapeutically effective amount of tomatidine and rapamycin, said bacteria selected from the group consisting of Streptococcus, Actinomyces, Veillonella, Fusobacterium, Porphromonas, Prevotella, Treponema, Nisseria, Haemophilis, Eubacteria, Lactobacterium, Capnocytophaga, Eikenella, Leptotrichia, Peptostreptococcus, Staphylococcus, Propionibacterium, Chlamydia, Shigella flexneri, Mycoplasma bacteria, H. pylori, and Streptomyces hygroscopicus.

14. A method of treating bladder cancer in a subject in need of such treatment, said method comprising administering to a microbiome of a subject with bladder cancer an effective amount of a bacterial composition, said method comprising administering a therapeutically effective amount of bacteria of a species found in the subject'"'"'s gut microbiome, wherein the bacteria has been modified using a CRISPR-Cas system to produce one of tomatidine or rapamycin.

15. The method of claim 14, wherein the bacteria is H. pylori.

16. The method as set forth in claim 14, further comprising administering a therapeutically effective amount of a bacterial composition comprising Streptomyces hygroscopicus in an amount effective to provide a therapeutically effective amount of rapamycin to the subject.

17. The method of claim 14, wherein the bacterial composition comprises Bacillus calmette-guerin.

18. The method of claim 14, wherein said Bacillus calmette-guerin also produces p53.

19. The method of claim 17, wherein the Bacillus calmette-guerin is further adapted to produce rapamycin.

20. The method of claim 14, wherein said method maintains or increases the muscle mass of the subject.